Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Critical Care Medicine

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CCM.0000000000001402PMID 26584195PMCID PMC5378312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

  2015cited by this paper
• Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome – Successful use of PET- CT and Anakinra in its diagnosis and treatment

  2015cited by this paper
• Clinical features and correct diagnosis of macrophage activation syndrome

  2015cited by this paper
• Pediatric Lung Transplantation

  2014cited by this paper
• Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients

  2014cited by this paper
• Macrophage Activation Syndrome Secondary to Human Monocytic Ehrlichiosis

  2014cited by this paper
• Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome

  2014cited by this paper
• Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome*.

  2014cited by this paper
• Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients.

  2014cited by this paper
• High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report

  2014cited by this paper
• Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome

  2013cited by this paper
• Association between Endothelial Dysfunction and Acute Brain Dysfunction during Critical Illness

  2013cited by this paper
• Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra

  2012cited by this paper
• Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment

  2012cited by this paper
• Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

  2012cited by this paper
• Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

  2012cited by this paper
• Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.

  2011cited by this paper
• Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

  2011influential reference
• Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.

  2011cited by this paper
• Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature

  2011cited by this paper
• Macrophage Activation Syndrome Treated with Anakinra

  2010cited by this paper
• Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation.

  2009cited by this paper
• Anakinra for Rheumatoid Arthritis: A Systematic Review

  2009cited by this paper
• Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis

  2008cited by this paper
• A case of macrophage activation syndrome successfully treated with anakinra

  2008cited by this paper
• High elevated ferritin levels and the diagnosis of HLH/Sepsis/SIRS/MODS/MAS

  2008cited by this paper
• The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

  2007cited by this paper
• Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.

  2007cited by this paper
• Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis.

  2006cited by this paper
• Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163*

  2006cited by this paper
• Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis

  2006cited by this paper
• Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

  2005cited by this paper
• Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome.

  2005cited by this paper
• Volume Index

  2005cited by this paper
• Haemophagocytic syndromes in adults: current concepts and challenges ahead.

  2005cited by this paper
• Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients—A postmortem clinicopathologic analysis

  2004cited by this paper
• 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

  2003cited by this paper
• 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

  2003cited by this paper
• The pathophysiology and treatment of sepsis.

  2003cited by this paper
• Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

  1997influential reference
• Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

  1994influential reference
• Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

  1994cited by this paper
• Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial

  1994cited by this paper
• Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.

  1992cited by this paper
• Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor.

  1991cited by this paper
• An expanded definition of the adult respiratory distress syndrome.

  1988influential reference
• Interleukin-1 and the pathogenesis of the acute-phase response.

  1984cited by this paper
• Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans.

  1981cited by this paper
• Human leukocytic pyrogen: purification and development of a radioimmunoassay.

  1977cited by this paper

• Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial

  2026cites this paper
• Early Antibiotic Therapy in Sepsis Without Shock: A Multimethod Study of Heterogeneous Treatment Effects in ICU Patients.

  2026cites this paper
• Cytokine storm

  2026cites this paper
• Temporal variation in haemophagocytic lymphohistiocytosis mortality.

  2026cites this paper
• The endothelial-immunothrombotic storm in viral sepsis: lessons from COVID-19

  2026cites this paper
• Serum H‐Ferritin‐To‐Ferritin Ratio as a Biomarker of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients With Hyperferritinemia

  2026cites this paper
• [Precision immunotherapy improves organ dysfunction in sepsis].

  2026cites this paper
• Steroid-Refractory Pembrolizumab-Induced Haemophagocytic Lymphohistiocytosis (HLH) Successfully Treated With Anakinra: A Case Report

  2026cites this paper
• Recognizing and Managing Hemophagocytic Lymphohistiocytosis in Adults in the Intensive Care Unit

  2026cites this paper
• Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?

  2025cites this paper
• IL-1beta expressing neutrophil extracellular traps in Legionella pneumophila infection

  2025cites this paper
• Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma

  2025cites this paper
• Hemophagocytic lymphohistiocytosis: an update in diagnostics, criteria, and treatment considerations.

  2025cites this paper
• Immune Dysregulation in Sepsis. A Narrative Review for the Clinicians

  2025cites this paper
• Role of inflammasomes in acute respiratory distress syndrome

  2025cites this paper
• Hemophagocytic Lymphohistiocytosis (HLH) or Macrophage Activation Syndrome (MAS)? A Lethal Case of Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Concurrent Autoimmune Disease

  2025cites this paper
• Macrophage Activation Syndrome: Not Just for Rheumatologists Anymore.

  2025cites this paper
• Recent advances of precision immunotherapy in sepsis

  2025cites this paper
• Hemophagocytic Lymphohistiocytosis.

  2025cites this paper
• Immunomodulation in Pediatric Sepsis: A Narrative Review

  2025influential citation
• Monocyte-macrophage membrane expression of IL-1R2 is a severity biomarker in sepsis

  2025cites this paper
• Liver injury in sepsis: manifestations, mechanisms and emerging therapeutic strategies

  2025cites this paper
• Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies

  2025cites this paper
• Interleukin-6 related signaling pathways as the intersection between chronic diseases and sepsis

  2025cites this paper
• Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy

  2025cites this paper
• Early management of hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a systematic literature review

  2025cites this paper
• Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective

  2025cites this paper
• Rapid and Continuous Simultaneous Monitoring of Interleukin-6 and Lactate Using a Bioelectronic Sensor Platform: toward Early Sepsis Prediction.

  2025cites this paper
• TM9SF1 as a Novel Prognostic Biomarker for Sepsis Severity and Mortality: A Longitudinal Study

  2025cites this paper
• The immunology of sepsis: translating new insights into clinical practice

  2025cites this paper
• Progress on diagnosis and treatment of multisystem inflammatory syndrome in children

  2025cites this paper
• Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial

  2025cites this paper
• Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.

  2025cites this paper
• Bloodstream Infection-induced Neuroinflammation: from Systemic Infection To Brain Invasion

  2025cites this paper
• YOD1 promotes ferroptosis in acute lung injury by deubiquitination of NCOA4

  2025cites this paper
• Endotoxin retention in adipose tissue leading to persistent hypotension in catecholamine-dependent acute obstructive suppurative cholangitis

  2025cites this paper
• The Interleukin Network in Sepsis: From Cytokine Storm to Clinical Applications

  2025cites this paper
• Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: deciphering underlying disease mechanisms to optimize diagnosis and therapy

  2025cites this paper
• Thrombocytopenia in Critically Ill Children: A Review for Practicing Clinicians

  2025cites this paper
• The Novel Role of the Expression of Toll-like Receptors TLR-5, TLR-6, and TLR-9 and Associated Up-Regulation of Programmed Cell Death 1 Receptor (PD-1) and Its Ligand (PD-L1) in Lung Sepsis

  2025cites this paper
• Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS)

  2025cites this paper
• Two dramatically different clinical scenarios of neonatal Echovirus-11 infection in late preterm male twins: a case report and review of the literature

  2025cites this paper
• Severe Dengue Associated With Hemophagocytic Lymphohistiocytosis (HLH) in an Adult ICU

  2025cites this paper
• Management dilemma in choosing evolving treatments in neutropenic septic shock

  2025cites this paper
• Future management of sepsis in liver cirrhosis

  2025cites this paper
• Identifying Hemophagocytic Lymphohistiocytosis and Describing Outcomes Using Computable Phenotypes: A Retrospective Cohort Study (Preprint)

  2025cites this paper
• The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential

  2025cites this paper
• Reassessing sepsis research: new clues for old players and new players for an old symptom to improve patient outcomes

  2025cites this paper
• Research Progress on Diagnosis and Treatment of Hemophagocytic Syndrome

  2025cites this paper
• Sepsis subtypes and differential treatment response to vitamin C: biological sub-study of the LOVIT trial

  2025cites this paper
• Whole blood ratio of CDK1/CX3CR1 mRNA expression combined to lactate refines the prediction of ICU mortality in septic patients in the Sepsis-3 era: a proof-of-concept study

  2025cites this paper
• Integrative analysis of crosstalk genes and diagnostic biomarkers in lupus-associated osteoporosis

  2025cites this paper
• Unraveling immunosenescence in sepsis: from cellular mechanisms to therapeutics

  2025cites this paper
• Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies.

  2025cites this paper
• Targeting the NLRP3 inflammasome in sepsis: Molecular mechanisms and therapeutic strategies.

  2025cites this paper
• Role of anakinra in the management of children with severe dengue

  2025cites this paper
• Biological drivers of the host response in sepsis

  2025cites this paper
• Haemophagocytic lymphohistiocytosis in pregnancy and the postpartum: A case series from the national HLH network.

  2025cites this paper
• SpyTag-PEGylated probiotics delivering IL-1Ra modulate gut-lung crosstalk to mitigate septic lung injury.

  2025cites this paper
• Dexamethasone chronotherapy of COVID-19 patients admitted to intensive care unit: an exploratory study

  2025cites this paper
• IGFBP6 orchestrates antiinfective immune collapse in murine sepsis via prohibitin-2–mediated immunosuppression

  2025cites this paper
• Hyperferritinemia and Macrophage Activation Syndrome in Septic Shock: Recent Advances with a Pediatric Focus (2020–2025)

  2025cites this paper
• Real-World Tocilizumab Use in Pediatric Inpatients.

  2025cites this paper
• Differential protein expression and enriched pathways in pediatric sepsis: identification of novel brain-associated biomarkers revealed through proteomic profiling

  2025cites this paper
• Successful Treatment of Severe Purpura Fulminans With Anakinra.

  2025cites this paper
• The Role of Inflammasomes in LPS and Gram-Negative Bacterial Sepsis

  2025cites this paper
• Platelets in Neonatal Sepsis: Beyond Clotting, From Silent Players to Immune Orchestrators

  2025cites this paper
• Sepsis-Induced Cardiomyopathy and Cardiac Arrhythmias: Pathophysiology and Implications for Novel Therapeutic Approaches

  2025cites this paper
• Cytokines in sepsis: a critical review of the literature on systemic inflammation and multiple organ dysfunction

  2025influential citation
• Decoding IL-1 receptor 1 and 2 expression profiles across organs in sepsis

  2025cites this paper
• Hyperferritinemia is Associated with Thrombocytopenia and Increased Mortality Risk in Adult Sepsis Patients: A Retrospective Study of Two Observational Cohorts

  2025cites this paper
• Potential of biomarker-based enrichment strategies to identify critically ill patients for emerging cell death interventions

  2025cites this paper
• Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis

  2024cites this paper
• Review of the Predictive Value of Biomarkers in Sepsis Mortality

  2024cites this paper
• Towards personalized medicine: a scoping review of immunotherapy in sepsis

  2024cites this paper
• Characteristics and Risk Factors for Pediatric Sepsis

  2024cites this paper
• An exploratory analysis of routine ferritin measurement upon admission and the prognostic implications of low-grade ferritinemia during inflammation.

  2024cites this paper
• The NLRP3 inflammasome is essential for IL-18 production in a murine model of macrophage activation syndrome

  2024cites this paper
• Inhibition of PI3K p110δ rebalanced Th17/Treg and reduced macrophages pyroptosis in LPS-induced sepsis.

  2024cites this paper
• Targeted treatments for immune dysregulation in inborn errors of immunity

  2024cites this paper
• Specific and Non-specific Aspects and Future Challenges of ICU Care Among COVID-19 Patients with Obesity: A Narrative Review

  2024cites this paper
• Immunotherapy in the context of sepsis-induced immunological dysregulation

  2024cites this paper
• Pathogenesis of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome: A Case Report and Review of the Literature

  2024cites this paper
• Charting the course for improved outcomes in chronic critical illness: therapeutic strategies for persistent inflammation, immunosuppression, and catabolism syndrome (PICS).

  2024cites this paper
• Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

  2024cites this paper
• Systems-wide view of host-pathogen interactions across COVID-19 severities using integrated omics analysis

  2024cites this paper
• Nitrite Attenuates the In Vitro Inflammatory Response of Immune Cells to the SARS-CoV-2 S Protein without Interfering in the Antioxidant Enzyme Activation

  2024cites this paper
• Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities

  2024cites this paper
• The pathophysiology of sepsis and precision-medicine-based immunotherapy

  2024cites this paper
• The critical role of neutrophil-endothelial cell interactions in sepsis: new synergistic approaches employing organ-on-chip, omics, immune cell phenotyping and in silico modeling to identify new therapeutics

  2024cites this paper
• Use of high-dose steroid therapy: addition of anakinra in the treatment of severe COVID-19

  2024cites this paper
• Hemophagocytic lymphohistiocytosis after solid organ transplantation: A challenge for clinicians.

  2024cites this paper
• Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19

  2024cites this paper
• The NLRP3 inflammasome is essential for IL-18 production in a murine model of macrophage activation syndrome

  2024cites this paper
• The latest advances in the use of biological DMARDs to treat Still’s disease

  2024cites this paper
• IL-1 Family Blockade in Cytokine Storm Syndromes.

  2024cites this paper
• Hemophagocytic lymphohistiocytosis and macrophage activation syndrome: two rare sides of the same devastating coin

  2024cites this paper
• The critical impacts of cytokine storms in respiratory disorders

  2024cites this paper
• From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU

  2024cites this paper
• Treatment of multisystem inflammatory syndrome in children

  2024cites this paper